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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of a health claim related to zinc and 
normal function of the immune system pursuant to Article 14 of Regulation 
(EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
2,3
 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted pursuant to Article 14 
of Regulation (EC) No 1924/2006 via the Competent Authority of France, the EFSA Panel on Dietetic Products, 
Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim 
related to zinc and normal function of the immune system. The food constituent, zinc, which is the subject of the 
health claim is sufficiently characterised. Normal function of the immune system is a beneficial physiological 
effect for infants and young children. A claim on zinc and function of the immune system in the general 
population has already been assessed with a favourable outcome. The Panel considers that the role of zinc in 
normal function of the immune system applies to all ages, including infants and young children (from birth to 
three years). The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of zinc and normal function of the immune system. The following wording reflects the scientific evidence: 
“zinc contributes to normal function of the immune system”. 
© European Food Safety Authority, 2014 
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SUMMARY 
Following an application from Specialised Nutrition Europe (formerly IDACE), submitted for 
authorisation of a health claim pursuant to Article 14 of Regulation (EC) No 1924/2006 via the 
Competent Authority of France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
was asked to deliver an opinion on the scientific substantiation of a health claim related to zinc and 
normal function of the immune system. 
The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
The food constituent that is the subject of the health claim is zinc, which is an essential nutrient and is 
measurable in foods by established methods. The Panel considers that zinc is sufficiently 
characterised. 
The claimed effect proposed by the applicant is “zinc helps to support a healthy immune system”. The 
target population proposed by the applicant is infants and young children from birth to three years of 
age. The Panel considers that normal function of the immune system is a beneficial physiological 
effect for infants and young children. 
A claim on zinc and normal function of the immune system in the general population has already been 
assessed with a favourable outcome. The conclusion of the Panel was based on the essentiality of zinc 
with respect to the function of the immune system. 
The Panel considers that the role of zinc in normal function of immune system applies to all ages, 
including infants and young children (from birth to three years). 
The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of zinc and normal function of the immune system. 
The following wording reflects the scientific evidence: “zinc contributes to normal function of the 
immune system”. 
The Panel considers that, in order to bear the claim, follow-on formulae should comply with the 
criteria of composition of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally 
complete foods for special medical purposes intended for use by infants and nutritionally complete 
foods for special medical purposes other than those intended for use by infants should comply with the 
criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-based 
foods and baby foods for infants and young children should comply with the criteria of composition of 
these foods as laid down in Directive 2006/125/EC; other foodstuffs intended for infants and young 
children should provide at least 15 % of the reference values for nutrition labelling for foods intended 
for infants and young children as laid down in Directive 2006/141/EC. Such amounts can be easily 
consumed as part of a balanced diet. The target population is infants and children up to three years. A 
Tolerable Upper Intake Level has been established for zinc in this age group. 
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BACKGROUND 
Regulation (EC) No 1924/2006
4
 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of this 
Regulation, are authorised in accordance with this Regulation, and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Articles 14 to 17 of this 
Regulation lay down provisions for the authorisation and subsequent inclusion of reduction of disease 
risk claims and claims referring to children’s development and health in a Community list of permitted 
claims. 
According to Article 15 of this Regulation, an application for authorisation shall be submitted by the 
applicant to the national competent authority of a Member State, which will make the application and 
any supplementary information supplied by the applicant available to the European Food Safety 
Authority (EFSA). 
STEPS TAKEN BY EFSA 
 The application was received on 14/02/2008. 
 The scope of the application was proposed to fall under a health claim referring to children’s 
development and health. 
 On 26/03/2008, during the validation process of the application, EFSA sent a request to the 
applicant to provide missing information. 
 On 09/12/2013, EFSA received the missing information as submitted by the applicant. 
 The scientific evaluation procedure started on 21/01/2014. 
 During its meeting on 10/04/2014, the NDA Panel, having evaluated the data submitted, 
adopted an opinion on the scientific substantiation of a health claim related to zinc and normal 
function of the immune system. 
TERMS OF REFERENCE 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16 of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on 
the scientific substantiation of a health claim related to zinc and normal function of the immune 
system. 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation for the marketing 
of zinc, a positive assessment of its safety, nor a decision on whether zinc is, or is not, classified as a 
foodstuff. It should be noted that such an assessment is not foreseen in the framework of Regulation 
(EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the authorisation 
procedure foreseen in Article 17 of Regulation (EC) No 1924/2006. 
                                                     
4 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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INFORMATION PROVIDED BY THE APPLICANT 
Applicant’s name and address: Specialised Nutrition Europe (formerly IDACE), 9–31 Avenue des 
Nerviens, 1040 Brussels, Belgium. 
Food/constituent as stated by the applicant 
According to the applicant, the food constituent for which the claim is made is zinc. 
Health relationship as claimed by the applicant 
According to the applicant, zinc supplementation showed, for instance, a positive impact on the 
lymphocyte proliferation and the lipopolysaccharide-specific immunoglobulin G response in infants 
(Raqib et al., 2004) or on shigellacidal antibody response and on the proportions of CD20+ and 
CD20+CD38+ cells (Rahman et al., 2005). Several very recent trials and meta-analysis of studies done 
on infants and young children (Aggarwal et al., 2007; Garenne et al., 2007; Lazzerini et al., 2008; 
Lukacik et al., 2008) have confirmed that the impact of zinc supplementation on infants and young 
children is positive - reduction of the duration and severity of acute and persistent diarrhoea, thereby 
preventing and providing aid in the treatment of diarrhoea - even if there are some inconsistencies 
among studies owing to heterogeneity in zinc dosages, endpoints and study design. Zinc 
supplementation in infants and young children (especially > 6 months) is positive and helps prevent 
and treat respiratory infections (Brooks et al., 2004; Mahalanabis et al., 2004; Aggarwal et al., 2007). 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: “zinc helps to support a 
healthy immune system”. 
Equivalent wordings: “zinc is necessary for a healthy immune system”, “zinc is important for the 
normal development of immune function”, “zinc plays an important role for the function of natural 
defences”, “zinc helps to support the normal function of immune system”, “zinc participates in the 
normal function of immune system”, “zinc is needed for the normal function of immune system”, 
“zinc supports the normal function of immune system”. 
Specific conditions of use as proposed by the applicant 
According to the applicant, the target population is infants and young children from birth to three 
years of age. 
According to the applicant, the quantity needed to achieve the claimed effect is: 
 For follow-on formulae, the content in zinc should be within the range set in Directive 
2006/141/EC. 
 For dietary foods for special medical purposes, the content in zinc should be within the range 
set in Directive 1999/21/EC. 
 For processed cereal-based foods and baby foods, the content in zinc should be within the 
range set in Directive 2006/125/EC. 
 For processed cereal-based foods and baby foods, the content in zinc should reach at least 
15 % of the Nutrient Reference Values set in Directive 2006/125/EC, i.e. 15 % of 4 mg per 
100 g or 100 mL or per serving, as reconstituted. 
 For foods intended for infants and young children other than follow-on formulae, processed 
cereal-based foods and baby foods, the content in zinc should reach at least 15 % of the 
Nutrient Reference Values set in Directive 2006/141/EC, i.e. 15 % of 5 mg per 100 mL 
product ready for use. 
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ASSESSMENT 
1. Characterisation of the constituent 
The food constituent that is the subject of the health claim is zinc, which is an essential nutrient and is 
measurable in foods by established methods. Different forms of zinc occur naturally in foods and are 
authorised for addition to foods and for use in food supplements (Annex II of Regulation (EC) No 
1925/2006,
5
 Annex II of Directive 2002/46/EC,
6
 Annex III of Directive 2006/141/EC,
7
 Annex IV of 
Directive 2006/125/EC,
8
 Directive 2001/15/EC
9
). This evaluation applies to zinc naturally present in 
foods and those forms authorised for addition to foods (Annex II of Regulation (EC) No 1925/2006, 
Annex II of Directive 2002/46/EC, Annex III of Directive 2006/141/EC, Annex IV of Directive 
2006/125/EC, Directive 2001/15/EC). 
The Panel considers that the food constituent, zinc, which is the subject of the health claim, is 
sufficiently characterised. 
2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is “zinc helps to support a healthy immune system”. The 
target population proposed by the applicant is infants and young children from birth to three years of 
age. 
The Panel considers that the normal function of the immune system is a beneficial physiological effect 
for infants and young children. 
3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed and Cochrane database, using the search terms: 
“zinc”, “child-preschool in age OR infant in age OR infant newborn in age”, “clinical trial OR review 
OR meta-analysis”, “zinc deficiency OR zinc OR zinc compounds” and a time frame between 2003 
and 2008. Studies on zinc combined with other micronutrients, in children older than three years old 
and on outcomes other than the immune system (i.e. growth, anaemia, cognitive and motor 
development, zinc status) were excluded. 
The applicant identified 14 human studies, including nine human intervention studies (Brooks et al., 
2004; Mahalanabis et al., 2004; Rahman et al., 2005; Raqib et al., 2006; Bose et al., 2006; Coles et al., 
2007; Garenne et al, 2007; Tielsch et al., 2007; Walker et al., 2007) and five meta-analyses or 
protocols for meta-analyses of human intervention studies (Abba and Garner, 2007; Aggarwal et al., 
2007; Haider et al., 2008; Lazzerini and Ronfani, 2008; Lukacik et al., 2008) as relevant to the claim. 
The Panel has already assessed a claim on zinc and normal function of the immune system with a 
favourable outcome (EFSA NDA Panel, 2009). The target population was the general population. The 
conclusion of the Panel was based on the essentiality of zinc with respect to the function of the 
immune system. Zinc deficiency is associated with a decline in most aspects of immune function and 
renders people more susceptible to infections. 
The Panel considers that the role of zinc in normal function of the immune system applies to all ages, 
including infants and young children (from birth to three years). 
                                                     
5 Regulation (EC) No 1925/2006 of the European Parliament and of the Council of 20 December 2006 on the addition of 
vitamins and minerals and of certain other substances to foods. OJ L 404, 30.12.2006, p. 26–38. 
6 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of 
the Member States relating to food supplements. OJ L 183, 12.7.2002, p. 51–57. 
7 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending 
Directive 1999/21/EC Text with EEA relevance. OJ L 401, 30.12.2006, p. 1–33. 
8 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
9 Commission Directive 2001/15/EC of 15 February 2001 on substances that may be added for specific nutritional purposes 
in foods for particular nutritional uses. OJ L 52, 22.2.2001, p. 19–25. 
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The Panel concludes that a cause and effect relationship has been established between the dietary 
intake of zinc and normal function of the immune system. 
4. Panel’s comments on the proposed wording 
The Panel considers that the following wording reflects the scientific evidence: “zinc contributes to 
normal function of the immune system”. 
5. Conditions and restrictions of use 
The Panel considers that in order to bear the claim: 
 follow-on formulae should comply with the criteria of composition of follow-on formulae as 
laid down in Directive 2006/141/EC; 
 nutritionally complete foods for special medical purposes intended for use by infants and 
nutritionally complete foods for special medical purposes other than those intended for use by 
infants should comply with the criteria of composition of these foods as laid down in Directive 
1999/21/EC
10
; 
 processed cereal-based foods for infants and young children should comply with the criteria of 
composition of these foods as laid down in Directive 2006/125/EC; 
 other foodstuffs intended for infants and young children should provide at least 15 % of the 
reference values for nutrition labelling for foods intended for infants and young children as 
laid down in Directive 2006/141/EC. 
Such amounts can be easily consumed as part of a balanced diet. The target population is infants and 
children up to three years. A Tolerable Upper Intake Level (UL) has been established for zinc in this 
age group, and has been set at 7 mg/day (SCF, 2002). 
CONCLUSIONS 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, zinc, which is the subject of the health claim is sufficiently 
characterised. 
 The claimed effect proposed by the applicant is “zinc helps to support a healthy immune 
system”. The target population proposed by the applicant is infants and young children from 
birth to three years of age. Normal function of the immune system is a beneficial physiological 
effect for infants and young children. 
 A cause and effect relationship has been established between the dietary intake of zinc and 
normal function of the immune system. 
 The following wording reflects the scientific evidence: “zinc contributes to normal function of 
the immune system”. 
 In order to bear the claim, follow-on formulae should comply with the criteria of composition 
of follow-on formulae as laid down in Directive 2006/141/EC; nutritionally complete foods 
for special medical purposes intended for use by infants and nutritionally complete foods for 
special medical purposes other than those intended for use by infants should comply with the 
criteria of composition of these foods as laid down in Directive 1999/21/EC; processed cereal-
                                                     
10 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, 
p. 29–36. 
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based foods and baby foods for infants and young children should comply with the criteria of 
composition of these foods as laid down in Directive 2006/125/EC; other foodstuffs intended 
for infants and young children should provide at least 15 % of the reference values for 
nutrition labelling for foods intended for infants and young children as laid down in Directive 
2006/141/EC. Such amounts can be easily consumed as part of a balanced diet. The target 
population is infants and children up to three years. A Tolerable Upper Intake Level (UL) has 
been established for zinc in this age group, and has been set at 7 mg/day (SCF, 2002). 
DOCUMENTATION PROVIDED TO EFSA 
Health claim application on zinc and function of the immune system pursuant to Article 14 of 
Regulation (EC) No 1924/2006 (Claim serial No: 0109_FR). February 2008. Submitted by Specialised 
Nutrition Europe (formerly IDACE). 
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